Adenoviral vector programs can move faster when development begins with the right balance of structure and flexibility. In this Fierce Biotech article, SK pharmteco explains why adenovirus manufacturing should not rely on a rigid, one-size-fits-all platform. Instead, successful programs benefit from an adaptive framework that standardizes what can be standardized while tailoring key decisions to the biology of each construct.
The article explores critical considerations across upstream development, harvest optimization, downstream purification, residual clearance, formulation, analytical strategy, viral banking, viral clearance, and GMP readiness. It also highlights why early understanding of the process can help developers reduce risk, improve scalability, and make more informed decisions before entering GMP manufacturing.
Learn how SKyvec Adeno supports adenoviral vector programs with a structured yet adaptable development approach designed to help advance complex therapies from process development to clinical manufacturing.
Frequently Asked Questions
What is adaptive adenoviral vector development?
Adaptive adenoviral vector development combines proven platform knowledge with program-specific decisions, helping teams tailor process development, analytics, purification, formulation, and GMP planning to each construct’s needs.
Why is adenovirus manufacturing difficult to standardize?
Adenoviral vector programs can vary by construct design, cell line behavior, harvest conditions, purification needs, analytical requirements, and formulation goals, making flexibility important during development.
How can early process understanding reduce GMP risk?
Early process understanding can help identify scalability challenges, analytical gaps, clearance considerations, and documentation needs before GMP manufacturing, supporting a smoother path into clinical supply.
How does SKyvec Adeno support adenoviral vector programs?
SKyvec Adeno provides a structured yet adaptable approach to adenoviral vector development, supporting process development, analytical readiness, viral banking, viral clearance planning, and GMP manufacturing preparation.
Authors:
Tatiana Nanda, VP, Technical Development and Analytical Services, SK pharmteco;
Christopher Nieder, Senior Director, Head of Technical Development, SK pharmteco;
Mardhani Aparajithan, Director, MSAT, SK pharmteco; and
Robert Brousseau, Senior Content Manager, SK pharmteco